Literature DB >> 10335187

A model for patient participation in quality of life measurement to improve rehabilitation outcomes.

M B Callahan1, L LeSage, S Johnstone.   

Abstract

Health-related quality of life (HRQOL) measurement is being used to assess end-stage renal disease (ESRD) patients' functional status and well-being from the patient's perspective. Research shows that HRQOL can screen for patients at high risk for death, hospitalization, treatment adherence, and depression. This study investigated whether patient goal setting and interdisciplinary collaboration and support could increase HRQOL scores in ESRD patients on chronic maintenance hemodialysis. Differences were found to be statistically significant in two of the MOS Short Form 36 (SF-36) categories (role physical and role emotional) following the intervention at the 95% confidence interval using a t-test statistic. This indicates that the intervention had a positive impact on patient perceptions of their health status. Eighty-seven percent indicated that there had been at least some progress made in reaching the goal. The results of this study support the utilization of HRQOL data at the facility level to improve patient's perceptions of their health status. A further study is needed to examine the long-term impact on HRQOL and other patient outcome measures through consistent use of this intervention.

Entities:  

Mesh:

Year:  1999        PMID: 10335187

Source DB:  PubMed          Journal:  Nephrol News Issues        ISSN: 0896-1263


  2 in total

1.  Use of Electronic Patient Reported Outcomes in Clinical Nephrology Practice: A Qualitative Pilot Study.

Authors:  Kara Schick-Makaroff; Kaitlyn Tate; Anita Molzahn
Journal:  Can J Kidney Health Dis       Date:  2019-09-30

2.  An Evidence-Based Theory About PRO Use in Kidney Care: A Realist Synthesis.

Authors:  Kara Schick-Makaroff; Adrienne Levay; Stephanie Thompson; Rachel Flynn; Richard Sawatzky; Onouma Thummapol; Scott Klarenbach; Mehri Karimi-Dehkordi; Joanne Greenhalgh
Journal:  Patient       Date:  2021-06-10       Impact factor: 3.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.